#China #Xi'an #Tianlong #Blood Screening #transfusion safety

Enhancing Blood Safety: Tianlong's Commitment on World AIDS Day 2025

On November 28, 2025, as the global community observes World AIDS Day, Tianlong Science & Technology has once again emphasized its unwavering commitment to improving transfusion safety worldwide. The company has unveiled its latest integrated solution for nucleic acid blood screening, a significant advancement in the detection of transfusion-transmitted infections, including HIV.

The Need for Improved Blood Safety

Transfusion safety remains one of the most crucial measures to protect individuals from transfusion-transmitted infections. With the rise of HIV and other blood-borne viruses, ensuring the safety of blood products is paramount. Tianlong's new technology promises to enhance screening accuracy, enabling laboratories to detect infections such as HBV, HCV, and HIV in their early stages. This capability supports global public health initiatives and fosters confidence in each blood donation.

Fully Automated Workflow for Blood Screening

Central to Tianlong's innovative solution is the Aurora PANA X6, a fully automated nucleic acid extraction system designed for blood donation centers and large-scale screening programs. Coupled with the Gentier 96 Real-Time PCR System, this platform enables an efficient process known as “Sample-in, Result-out.” This cutting-edge system integrates various essential functions:

• - Original tube loading and barcode identification
• - Automated opening and closing
• - Direct sample collection
• - Nucleic acid extraction
• - PCR setup and amplification

By streamlining these steps, Tianlong’s solution significantly reduces manual handling, minimizes contamination risks, and enhances operational efficiency.

High-Throughput Capability for Large Volume Screening

The Aurora PANA X6 boasts an impressive capacity, processing up to 576 samples per run and 1,152 samples daily. This high throughput is essential for meeting the demands of large-scale blood screening programs. The unique feature of loading original collection tubes ensures a controlled and consistent operation, reducing the chances of cross-contamination.

Flexible Screening Modalities and Direct Pooling

Another highlight of Tianlong’s system is its capacity for direct pooling in deep-well plates, eliminating the need for additional collection tubes. The platform supports both individual tests and 6-in-1 pool testing, allowing labs to balance efficiency with sensitivity. This flexibility is vital for laboratories aiming to optimize their testing protocols while ensuring accurate results.

Enhancing Reliability with Robust Safety Features

The platform's design incorporates independent workspaces, HEPA filtration, UV disinfection, controlled airflow, and a drip-proof design, ensuring a high level of biosafety in demanding laboratory environments. The commitment to maintaining stringent biosafety protocols underscores Tianlong’s dedication to creating a safe testing atmosphere.

Sensitive NAT Reagents for Early Infection Detection

Complementing the automated platform, Tianlong uses highly sensitive NAT reagents from KHB, which utilize qualitative real-time PCR in a convenient all-in-one format. This reagent system is tailored to detect HBV, HCV, HIV-1, and HIV-2, even at low viral loads. By identifying infections during the window period, laboratories can significantly reduce the risk of transfusion-transmitted diseases and enhance the overall safety of the blood supply.

A Collective Mission for Life Protection

On this essential day, the capability of early detection highlighted by Tianlong’s innovative solution reiterates the shared commitment to protecting lives associated with blood donations and transfusions. Li Ming, CEO of Tianlong, stated, "On World AIDS Day, we are reminded that every safe transfusion represents a promise of protection for another human life. Our mission is to equip laboratories with solutions that enhance accuracy, strengthen biosafety, and support global efforts to prevent HIV transmission."

About Tianlong

Founded in 1997, Tianlong Science and Technology is a pioneer in genetic testing and molecular diagnostics. Together with its subsidiary, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), Tianlong has established five core technology platforms: immunodiagnostics, biochemistry, molecular diagnostics, POCT, and mass spectrometry. These platforms cater to various fields, including clinical diagnostics, blood donation centers, epidemic prevention in veterinary medicine, and food safety. Tianlong is committed to advancing healthcare solutions through innovative technologies.

For additional information, visit Tianlong's official website and follow them on LinkedIn, Facebook, and Twitter.